Monoclonal antibodies against spore antigens of Bacillus anthracis.

FEMS Microbiology Immunology
A P PhillipsR Quinn

Abstract

A murine monoclonal antibody produced against heat inactivated spores of Bacillus anthracis Ames, reacted with live or inactivated spores of several anthrax strains in indirect immunofluorescence (IF) tests. The reactive anthrax strain gave only a moderate degree of reaction. No staining of anthrax vegetative cells was observed. The monoclonal did not react with spores of non-anthrax Bacillus strains that gave cross reactions with mouse hyperimmune antiserum raised against Ames spores. The staining of individual spores in B. anthracis preparations was more heterogeneous with the monoclonal antibody than with the hyperimmune serum. Evidence is produced that the epitope for this monoclonal is not stable during long-term storage of inactivated spore preparations, and is not fully available for reaction with antibody until late in spore maturation. The monoclonal did not react by immunoblotting (Western blotting) of spore extracts. A monoclonal antibody produced against Ames spore extracts reacted with about 1% of Ames spores in IF tests, but not reproducible reactions with other anthrax strains were recorded. This monoclonal interacted with three bands in Western blots of anthrax spore extracts.

References

May 1, 1986·Infection and Immunity·B E IvinsS H Leppla
Aug 3, 1987·Journal of Immunological Methods·A P PhillipsA J Capey
Feb 1, 1988·Infection and Immunity·J W Ezzell, T G Abshire
Jan 1, 1983·Infection and Immunity·J D Ristroph, B E Ivins
Jan 1, 1984·Journal of Clinical Microbiology·H B ColeR J Doyle
Dec 1, 1983·Applied and Environmental Microbiology·A P Phillips, K L Martin
Sep 1, 1984·Journal of General Microbiology·R QuinnA P Phillips
Jul 1, 1962·Journal of General Microbiology·J R NORRIS

❮ Previous
Next ❯

Citations

Sep 4, 1999·Journal of Applied Microbiology·P Longchamp, T Leighton
Sep 6, 2000·Letters in Applied Microbiology·P Longchamp, T Leighton
Dec 18, 2013·World Journal of Microbiology & Biotechnology·Jenia A M TuftsShawn P Ryan
Apr 18, 2002·Proceedings of the National Academy of Sciences of the United States of America·Bin ZhouKim D Janda
Jan 1, 1992·The Journal of Applied Bacteriology·P C TurnbullJ Melling
Jan 28, 2015·The Analyst·Jahir OrozcoJoseph Wang
May 1, 1989·The Journal of Applied Bacteriology·A P Phillips, J W Ezzell
Feb 24, 2001·Biosensors & Bioelectronics·S S IqbalJ P Chambers
Feb 1, 1997·Applied and Environmental Microbiology·J J Quinlan, P M Foegeding

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.